dsip mengengabe Ms. Cécile Bibiane Ndjebet Sengbe Pieh – Tuntimo

With respect to the newness criterion at 419.66(b)(1), the aprevo Cervical ACDF System received FDA Breakthrough Device designation effective September 15, 2023, under the name aprevo-C cervical interbody fusion device

With appropriate care, time, and support, the same neuroplastic mechanisms that once reinforced dependence can be harnessed to support healing and long-term recovery

Standard break periods run 4-6 weeks, roughly half the length of the preceding cycle

In the intermediate phase, spanning 1 to 3 weeks, the loss of oligodendrocytes and activation of glial cells continue, with signs of demyelination and acute axonal pathology becoming evident (Crawford, 2009

It remains available through compounding, which is legal but different from active FDA approval

Nearly half of the participants retained clinically meaningful weight loss even after treatment ended